Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S.

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...